Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Mt Sinai J Med. 2010 Nov-Dec;77(6):655–666. doi: 10.1002/msj.20223

Table 4.

Phase II Clinical Trials With EGFR Inhibitors in Patients With Glioblastoma.

Authors No. of
Patients		 Radiographic
Response Rates (%)		 PFS (mo) OS (mo)
Gefitinib
 Rich et al.26 57 0 2.0 9.9
 Lieberman et al.89 38 13 2.0 —
 Uhm et al.90 96 — 6.8 12.8
 Franceschi et al.91 16 0 2.1 6.2
Erlotinib
 Vogelbaum et al.92 16 25 5.2 —
 Raizer et al.93 31 0 2.3 —
 Cloughesy et al.94 48 8 — —
 Van den Bent et al.95 54 4 1.8 7.7

Abbreviations: EGFR, epidermal growth factor receptor; OS, overall survival; PFS, progression-free survival.